These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10910374)

  • 1. Doxorubicin-induced cardiomyopathy.
    Otero FJ; Boor PJ; Sheahan RG
    Am J Med Sci; 2000 Jul; 320(1):59-63. PubMed ID: 10910374
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4'-epi-doxorubicin.
    Villani F; Comazzi R; Lacaita G; Genitoni V; Guindani A; Martini A
    Int J Clin Pharmacol Ther Toxicol; 1983 Apr; 21(4):203-8. PubMed ID: 6574995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate dynamics in doxorubicin-induced cardiomyopathy.
    Lončar-Turukalo T; Vasić M; Tasić T; Mijatović G; Glumac S; Bajić D; Japunžić-Žigon N
    Physiol Meas; 2015 Apr; 36(4):727-39. PubMed ID: 25798626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline cardiotoxicity.
    Gasparini M
    Pediatr Hematol Oncol; 1994; 11(3):237-40. PubMed ID: 8060806
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
    Herman EH; Lipshultz SE; Rifai N; Zhang J; Papoian T; Yu ZX; Takeda K; Ferrans VJ
    Cancer Res; 1998 Jan; 58(2):195-7. PubMed ID: 9443390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin and doxorubicin in nude mice bearing human tumour xenografts.
    Ford CH; Richardson VJ; Pushpanathan C; Ali SK
    Anticancer Res; 1991; 11(5):1855-62. PubMed ID: 1768056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration.
    Toyoda Y; Okada M; Kashem MA
    J Thorac Cardiovasc Surg; 1998 Jun; 115(6):1367-73. PubMed ID: 9628680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing for doxorubicin cardiotoxicity.
    Henderson IC; Frei E
    N Engl J Med; 1979 Jun; 300(24):1393-4. PubMed ID: 440374
    [No Abstract]   [Full Text] [Related]  

  • 9. A colorful chemotherapy agent could be made less toxic.
    Kaiser J
    Science; 2020 Jul; 369(6499):18. PubMed ID: 32631876
    [No Abstract]   [Full Text] [Related]  

  • 10. Testing for doxorubicin cardiotoxicity.
    Wexler JP; Blaufox MD; Freeman LM
    N Engl J Med; 1979 Jun; 300(24):1393. PubMed ID: 440373
    [No Abstract]   [Full Text] [Related]  

  • 11. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy.
    Lebrecht D; Kirschner J; Geist A; Haberstroh J; Walker UA
    Cardiovasc Pathol; 2010; 19(5):e167-74. PubMed ID: 19747854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
    Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
    Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
    Bennink RJ; van den Hoff MJ; van Hemert FJ; de Bruin KM; Spijkerboer AL; Vanderheyden JL; Steinmetz N; van Eck-Smit BL
    J Nucl Med; 2004 May; 45(5):842-8. PubMed ID: 15136635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grape seed and skin extract protects against acute chemotherapy toxicity induced by doxorubicin in rat heart.
    Mokni M; Hamlaoui-Guesmi S; Amri M; Marzouki L; Limam F; Aouani E
    Cardiovasc Toxicol; 2012 Jun; 12(2):158-65. PubMed ID: 22290400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
    Torti FM; Porzig KJ; Gandara DR; Volberding P; Mitchell E; Meyers FJ; Kohler M; Gribble M
    Cancer Treat Rep; 1984 Dec; 68(12):1509-10. PubMed ID: 6595059
    [No Abstract]   [Full Text] [Related]  

  • 16. [Control of cardiac function during therapy with doxorubicin and other anthracyclines].
    Grille W; Johnsen K; Kolenda KD; Schöttler M; Löffler H
    Dtsch Med Wochenschr; 1985 Jul; 110(28-29):1134-7. PubMed ID: 3859399
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
    Cini-Neri G; Neri B
    Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity.
    DiSilvestro RA; Liu J; Klaassen CD
    Res Commun Mol Pathol Pharmacol; 1996 Aug; 93(2):163-70. PubMed ID: 8884987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction.
    Hydock DS; Lien CY; Schneider CM; Hayward R
    Med Sci Sports Exerc; 2008 May; 40(5):808-17. PubMed ID: 18408619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model.
    Kharin S; Krandycheva V; Tsvetkova A; Strelkova M; Shmakov D
    Fundam Clin Pharmacol; 2013 Aug; 27(4):364-72. PubMed ID: 22429163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.